SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Collateral Therapeutics (CLTX)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Silver Knife who wrote (9)2/25/2000 8:43:00 PM
From: JMarcus  Read Replies (1) of 35
 
Silver, I don't suppose you are still long CLTX. This thread has been dead for nearly a year. From today's action, it looks like CLTX is starting to make its big move. I had worried about the impact of the Jessie Gelsinger debacle upon a company like CLTX that uses the adenovirus for a gene vector. I spoke to a company rep. at an Informed Investors Forum a month or so ago and it turns out that there is little reason for concern. First, the company's therapy for growing new heart blood vessels is a one-shot administration, so there is no issue about developing an immune response that might flare up in a follow-on administrations of the therapy. Second, the heart muscle is much less susceptible to an immune response than other organs are. Third, the uptake of the vector into heart and vascular tissue is proving to be very rapid and thorough, so there is no real issue about the adenoviruses spreading to other areas in the body.

Bless my luck, I went long first thing this morning, before the big rise.

Marc
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News